Watson Danielle

SEC source: 0001213900-26-076883 · ownership.xml · derivative · entry 1

Watson Danielle · CIK 0001933818 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Represents the Issuer's restricted stock units (the "RSUs") granted to the Reporting Person under the Issuer's 2023 Equity Incentive Plan, as amended, pursuant to the approval of the Issuer's board of directors (the "Board"). Each vested RSU shall be settled by delivery to the Reporting Person of one share of the Issuer's common stock, $0.001 par value per share, upon satisfaction of the Conditions (as defined below).

F2 · derivative.exercise_date: The RSUs shall vest subject to the satisfaction of the following conditions (the "Conditions"): (i) occurrence of a closing of the merger (the "Closing") pursuant to a Merger Agreement dated June 22, 2026, among the Issuer, Cordis Acquisition, LLC, Fortitude Mining Holdings, Inc. and Fortitude Mining HoldCo, LLC; and (ii) (x) 1/4th of the RSUs shall vest on the three-month anniversary of the date of the Closing and (y) thereafter, 1/4th of the RSUs shall vest on each subsequent three-month anniversary of the initial vesting date, such that all of the RSUs shall fully vest on the one-year anniversary of the date of the Closing, (continued to footnote 3)

F3 · derivative.exercise_date: in each case provided that the Reporting Person is continuously employed in any capacity by the Issuer or any of its subsidiaries from the date of the Closing through each applicable vesting date, subject to certain qualifying termination rights by the Issuer or the Reporting Person.

F2 · derivative.expiration_date: The RSUs shall vest subject to the satisfaction of the following conditions (the "Conditions"): (i) occurrence of a closing of the merger (the "Closing") pursuant to a Merger Agreement dated June 22, 2026, among the Issuer, Cordis Acquisition, LLC, Fortitude Mining Holdings, Inc. and Fortitude Mining HoldCo, LLC; and (ii) (x) 1/4th of the RSUs shall vest on the three-month anniversary of the date of the Closing and (y) thereafter, 1/4th of the RSUs shall vest on each subsequent three-month anniversary of the initial vesting date, such that all of the RSUs shall fully vest on the one-year anniversary of the date of the Closing, (continued to footnote 3)

F3 · derivative.expiration_date: in each case provided that the Reporting Person is continuously employed in any capacity by the Issuer or any of its subsidiaries from the date of the Closing through each applicable vesting date, subject to certain qualifying termination rights by the Issuer or the Reporting Person.

SEC source: 0001213900-25-124718 · ownership.xml · derivative · entry 1

Watson Danielle · CIK 0001933818 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Represents Restricted Stock Units (the "RSUs") granted to the Reporting Person under the Issuer's 2023 Equity Incentive Plan (as amended, the "Plan") pursuant to the approval of the Issuer's board of directors. Each vested RSU shall be settled by delivery to the Reporting Person of one share of the Issuer's common stock, $0.001 par value per share, upon satisfaction of the Conditions (as defined below).

F2 · derivative.exercise_date: The RSUs shall vest subject to the satisfaction of all of the following conditions (the "Conditions"): (i) approval by the Issuer's shareholders of any amendment or modification to or restatement of the Plan, which, among other things, contemplates the award of the RSUs, and (ii)(x) 1/3rd of the RSUs shall vest on the one-year anniversary of the grant date (the "Initial Vesting Date") and (y) thereafter, 1/12th of the RSUs shall vest on each subsequent quarterly anniversary of the Initial Vesting Date (each an "Additional Initial Vesting Date" and together with the Initial Vesting Date, the "Vesting Dates"), such that all of the RSUs shall fully vest on the three-year anniversary of the grant date, (continued to footnote 3)

F3 · derivative.exercise_date: in each case provided that the Reporting Person is continuously employed by and is in good standing with the Issuer and the Reporting Person's employment agreement with the Issuer (the "Employment Agreement") is in effect, through each applicable Vesting Date. 100% of the RSUs shall vest (i) in the event of a Change of Control (as defined in the Plan) or (ii) if the Issuer achieves $250,000 or more of revenue in any fiscal quarter ending after the date hereof.

F2 · derivative.expiration_date: The RSUs shall vest subject to the satisfaction of all of the following conditions (the "Conditions"): (i) approval by the Issuer's shareholders of any amendment or modification to or restatement of the Plan, which, among other things, contemplates the award of the RSUs, and (ii)(x) 1/3rd of the RSUs shall vest on the one-year anniversary of the grant date (the "Initial Vesting Date") and (y) thereafter, 1/12th of the RSUs shall vest on each subsequent quarterly anniversary of the Initial Vesting Date (each an "Additional Initial Vesting Date" and together with the Initial Vesting Date, the "Vesting Dates"), such that all of the RSUs shall fully vest on the three-year anniversary of the grant date, (continued to footnote 3)

F3 · derivative.expiration_date: in each case provided that the Reporting Person is continuously employed by and is in good standing with the Issuer and the Reporting Person's employment agreement with the Issuer (the "Employment Agreement") is in effect, through each applicable Vesting Date. 100% of the RSUs shall vest (i) in the event of a Change of Control (as defined in the Plan) or (ii) if the Issuer achieves $250,000 or more of revenue in any fiscal quarter ending after the date hereof.

SEC source: 0001213900-25-063408 · ownership.xml · derivative · entry 1

Watson Danielle · CIK 0001933818 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2035-07-09

F1 · derivative.exercise_price: These options were granted to the Reporting Person effective as of July 9, 2025 (the "Effective Date"), pursuant to the approval of the compensation committee of the Issuer's board of directors.

F1 · price: These options were granted to the Reporting Person effective as of July 9, 2025 (the "Effective Date"), pursuant to the approval of the compensation committee of the Issuer's board of directors.

F2 · derivative.exercise_date: One-third of the options shall vest on the 12-month anniversary of the Effective Date, with an additional 8.333% of the options vesting on each of October 9, 2026 and thereafter on each successive three-month anniversary of such date, such that all options shall vest on July 9, 2028 (or earlier as described below), subject to the Reporting Person's continued employment with the Issuer through each applicable vesting date and subject to the terms of the Plan. These options shall become fully-vested and may be exercised at any time at the Reporting Person's election upon the Issuer receiving regulatory clearance for its MyoVista wavECG device or AI-ECG algorithm (subject to certain requirements) (or similar such product owned by the Issuer) from the U.S. Food and Drug Administration, or a Change of Control (as defined in the Reporting Person's Employment Agreement (the "EA")). As of the date of this filing, such regulatory clearance has not been received.

F3 · derivative.expiration_date: These options expire ten years from the Effective Date, unless terminated sooner in accordance with the Issuer's 2023 Equity Incentive Plan, as amended (the "Plan") or the underlying options grant agreement.

SEC source: 0001213900-25-005091 · ownership.xml · derivative · entry 1

Watson Danielle · CIK 0001933818 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2035-01-16

F1 · derivative.exercise_price: These options were granted to the Reporting Person effective as of January 16, 2025 (the "Effective Date"), pursuant to the approval of the compensation committee of the Issuer's board of directors.

F1 · price: These options were granted to the Reporting Person effective as of January 16, 2025 (the "Effective Date"), pursuant to the approval of the compensation committee of the Issuer's board of directors.

F2 · derivative.exercise_date: One-third of the options shall vest on the 12-month anniversary of the Effective Date, with an additional 8.333% of the options vesting on each of April 16, 2026 (the "Subsequent Vesting Date") and thereafter on each successive three-month anniversary of the Subsequent Vesting Date for the next seven fiscal quarters, subject to the Reporting Person's continued employment with the Issuer through each applicable vesting date and subject to the terms of the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"). These options shall become fully-vested and may be exercised at any time at the Reporting Person's election upon the Issuer receiving regulatory clearance for its MyoVista wavECG device or AI-ECG algorithm (subject to certain requirements) (or similar such product owned by the Issuer) from the U.S. Food and Drug Administration. As of the date of this filing, such regulatory clearance has not been received.

F3 · derivative.expiration_date: These options expire ten years from the Effective Date, unless terminated sooner in accordance with the Issuer's 2023 Plan or the underlying options grant agreement.

SEC source: 0000899243-23-009450 · doc4.xml · derivative · entry 1

Watson Danielle · CIK 0001933818 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2033-03-20

F1 · derivative.exercise_price: These options were granted to the Reporting Person effective as of March 20, 2023 (the "Effective Date"), pursuant to the approval of the Issuer's board of directors on March 20, 2023.

F1 · price: These options were granted to the Reporting Person effective as of March 20, 2023 (the "Effective Date"), pursuant to the approval of the Issuer's board of directors on March 20, 2023.

F2 · derivative.exercise_date: One-third of the options shall vest on the 12-month anniversary of the Effective Date, with an additional 8.333% of the options vesting on each of June 20, 2024 (the "Subsequent Vesting Date") and thereafter on each successive three-month anniversary of the Subsequent Vesting Date for the next seven fiscal quarters, subject to the Reporting Person's continued employment with the Issuer through each applicable vesting date and subject to the terms of the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"). These options shall become fully-vested and may be exercised at any time at the Reporting Person's election upon the Issuer receiving regulatory clearance for its MyoVista wavECG device (or similar such product owned by the Issuer) from the U.S. Food and Drug Administration. As of the date of this filing, such regulatory clearance has not been received.

F3 · derivative.expiration_date: These options expire ten years from the Effective Date, unless terminated sooner in accordance with the 2023 Plan or the underlying options grant agreement.